

# Resource Summary Report

Generated by [NIF](#) on Sep 22, 2026

## Illumina: NovaSeq 6000 Sequencing System

RRID:SCR\_016387

Type: Tool

---

### Proper Citation

Illumina: NovaSeq 6000 Sequencing System (RRID:SCR\_016387)

---

### Resource Information

**URL:** <https://www.illumina.com/systems/sequencing-platforms/novaseq.html>

**Proper Citation:** Illumina: NovaSeq 6000 Sequencing System (RRID:SCR\_016387)

**Description:** High-throughput platform used for next-generation sequencing (NGS) applications, including whole-genome, whole-exome, and whole-transcriptome sequencing. It is designed to provide a scalable, high-volume, and reliable way to sequence DNA and RNA for a wide range of genomic studies, from research to clinical applications.

**Synonyms:** Illumina NovaSeq 6000 Sequencing, Illumina NovaSeq 6000

**Resource Type:** instrument resource

**Keywords:** Instrument, equipment, sequencer, sequencing, dna, rna, platform, novaseq, sequencing system, USEdit

**Specification URL:** [https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/refs/heads/main/PDF/SCR\\_016387.pdf](https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/refs/heads/main/PDF/SCR_016387.pdf)

**Resource Name:** Illumina: NovaSeq 6000 Sequencing System

**Resource ID:** SCR\_016387

**Alternate IDs:** SCR\_020150, Model\_Number\_NovaSeq\_6000

**Alternate URLs:** <https://www.illumina.com/systems/sequencing-platforms/novaseq/specifications.html>

**Record Creation Time:** 20220129T080330+0000

**Record Last Update:** 20260919T195322+0000

---

### Ratings and Alerts

No rating or validation information has been found for Illumina: NovaSeq 6000 Sequencing System.

No alerts have been found for Illumina: NovaSeq 6000 Sequencing System.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 384 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Lasse Opsahl EL, et al. (2026) Fibroblast STAT3 Activation Drives Organ-Specific Premetastatic Niche Formation. *Cancer research*, 86(1), 22.

Barajas JM, et al. (2026) Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency. *Blood cancer discovery*, 7(1), 51.

Liu H, et al. (2026) The genomes of 5 mantises provide insights into sex chromosome evolution and Mantodea phylogeny clarification. *GigaScience*, 15.

Kelley RK, et al. (2026) T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(4), 694.

Huerga Encabo H, et al. (2026) Human TET2-Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny. *Blood cancer discovery*, 7(2), 287.

Maeda M, et al. (2026) CRISPR screen of human pancreatic cancer xenografts identifies a KLF5 proliferation vulnerability through epigenetic modifiers NCAPD2 and MTHFD1. *Molecular cancer*, 25(1).

Jiang S, et al. (2026) Transcription factor EGR1 orchestrates ferroptosis to mitigate sepsis-induced myocardial injury by enhancing ferroportin expression. *CytoJournal*, 23, 3.

Ponz-Sarvisé M, et al. (2026) Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study. *Cancer research communications*, 6(3), 673.

Spalato Ceruso M, et al. (2026) Adenosine A2B Receptor Promotes Tumor Progression and Metastases in Undifferentiated Pleomorphic Sarcoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(9), 1887.

Gholami S, et al. (2026) CXCR4 mRNA overexpression: an indicator of poor survival and predictor of response to immune checkpoint inhibitors in patients with metastatic colorectal cancer. *BMJ oncology*, 5(1), e001003.

DePuyt AE, et al. (2026) Type 1-polarized DC immunotherapeutic contains heterogeneous populations with IL-12p70 production restricted to a rare subset. *bioRxiv : the preprint server for biology*.

Kim S, et al. (2026) Gut microbiota transfer from autoimmune dry eye mice imprints stereotypic B cell receptor repertoires in the lacrimal gland and induces disease. *Frontiers in immunology*, 17, 1827057.

Bischoff AC, et al. (2026) Wilms Tumor 1-Expressing Stromal Cells Promote Pancreatic Cancer Progression. *Cancer research*, 86(2), 331.

Brodsky AL, et al. (2026) Combination Therapy with Copanlisib and Niraparib in Patients with Recurrent Endometrial and Ovarian Cancer (COPANIRA): Efficacy, Toxicity, and Translational Insights. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(7), 1234.

Sanz-Garcia E, et al. (2026) Investigating Early Kinetics in Plasma ctDNA and Peripheral T-cell Receptor Repertoire to Predict Treatment Outcomes to PD-1 Inhibitors in Head and Neck Squamous Cell Carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(4), 735.

Valentín López JC, et al. (2026) Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(12), 2413.

Zeng L, et al. (2026) Functional genomics reveals key gene families and molecular pathways for extreme cold survival in the khapra beetle. *BMC biology*, 24(1).

Kawazu M, et al. (2026) Genomic and Transcriptomic Analysis of High-Grade Endometrial Carcinoma Reveals Biological Heterogeneity and Molecular Classification Challenges. *Cancer research communications*, 6(4), 961.

Wang J, et al. (2026) Tumor-Resident *Streptococcus pneumoniae* Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma. *Cancer research*, 86(9), 2237.

Sahin IH, et al. (2026) Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancer. *NPJ precision oncology*, 10(1).